Drug Discovery of Biologics Primer 201 | CPE

- Level: Intermediate
- CPE: 1.0 Credits
- Time: 45 Minutes
Gain a strategic edge with Drug Discovery of Biologics Primer 201. Explore the behind-the-scenes challenges of bringing therapeutic antibodies to market, including antibody screening, CMC hurdles, cell banking, and key data requirements to drive smarter early-stage investment decisions.
- Learn the key factors in antibody development, screening, and production that influence business planning
- Explore how CMC (Chemistry, Manufacturing, and Controls) challenges affect development risks and commercialization outcomes
- Understand the transition criteria to assess if a drug candidate falls within the predicted parameters for development success
- Best Value: Unlimited Learning
- Purchase Single Course
Choose your subscription and start exploring a rich library of expert led, on-demand biotech training.
- Up to 12-month unlimited access
- Content designed for all skill levels: Beginner to Advanced
- CPE credits included with every course
- Learn at your own pace
- Choose the subscription plan that fits your goals
Get full access to this course with a one time purchase.
- 1-month access to all course material
- CPE credits included
- No subscription required
- Self-paced and on-demand
- Ideal for focused, one-off learning
- Overview
- Agenda
- Features
- Justify This Training
- FAQ
Watch Trailer
Agenda
-
Drug Discovery Workflow
Reviews the critical stages of drug development, from identifying and validating drug targets to selecting and optimizing lead biologic candidates.
-
Affinity Maturation and CMC Liabilities
Explains structure-based affinity maturation techniques, including targeted diversification and chain shuffling, and examines formulation-related CMC considerations.
-
Early Drug Candidate Selection
Explores the influence of an antibody candidate’s structure, including Fc and Fab regions, size, and molecular complexity, on its interactions with target molecules.
-
Antibody Diversity
Showcases therapeutic antibody classes, including canonical blocking antibodies, antibody-drug conjugates, antibody-like molecules, and immune response reactivators.
-
Discovery to Development Criteria
Examines the in vitro quantitative activity profile alongside in vivo efficacy and toxicity studies to inform dose estimation and advance candidate(s) to clinical development.
Features
- Closed Captioning in English, Spanish, French, French Canadian, Hindi, Japanese, Korean, Mandarin, Russian, Standard Arabic
- Transcripts in English, Spanish, French, French Canadian, Hindi, Japanese, Korean, Mandarin, Russian, Standard Arabic
- Course materials
- Real-time tracking
- Progress reporting
- Accessibility features
- Corporate account upgrades
- LinkedIn certificate attachment
- Verified certificates
Justify This Training
View our “Justify This Training” checklist and letter to craft a persuasive request that clearly shows the value of Biotech Primer training to your role and your company. This step-by-step guide helps you highlight ROI, align with business goals, and increase your chances of getting this course approved.
FAQ
Our Executive
Certifications
Cannot make our live class? Consider one of our Executive Certifications.

Biotechnology Executive Certification
- Level:Beginner
- CPE:14.50 Credits
- Time:12 Hours
- Total:12 Courses

Drug Development Executive Certification
- Level:Beginner
- CPE:13.50 Credits
- Time:10.5 Hours
- Total:12 Courses

Drug Manufacturing Executive Certification
- Level:Beginner
- CPE:14.50 Credits
- Time:10 Hours
- Total:11 Courses

Medical Device Executive Certification
- Level:Beginner
- CPE:12.00 Credits
- Time:8 Hours
- Total:9 Courses